ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN THE TREATMENT OF LEUKEMIA

Transplantationofautologousperipheralbloodstemcell(Auto-PBSCT)isawell-establishedmethodtoreconstitutehematopoiesisinpatientsreceivingmyeloablativeregimeninrecentloyears.ButPBSCTisrarelyusedinallogeneictransplantation,becauseofquestionsregardingofdurabilityofengraftmentandgraft-versus-hostdisease(GVHD).'G-CSFand/orGM-CSFmobilizedperipheralbloodstemcellfromnormaldonorcanbesafelycollectedforallogeneicPBSCT.2Froml995,webegantheresearchofAllo-PBSCTinthetreatmentofleukemia.MATERIALS…

Allogeneic peripheral blood stem cell transplantation in the treatment of leukemia

We reported 14 leukemia patients transplanted with allogeneic peripheral blood stem cells (Allo-PBSCT) of HLA identical sibling, AML 5, ALL 4, CML 5. There were 12 patients in their early stage of leukemia, 2 in late stage. They were 32 (25–42) years old, 10 male and 4 female. After conditioned with CTX and fTBI, G/GM-CSF mobilized donor’s peripheral blood mononuclear cells (MNC) 4.80 (2.46–8.43)×10⁸/kg and CD34+ cells 3.96 (1.01–10.08)x10⁶/kg were infused respectively. CSA and MTX used as GVHD prophylaxis. After Allo-PBSCT, WBC rose to 1.0×10⁹/L on day+17 (+12?+26) and platelet rose to 50×10⁹/L on day +27 (+19?+35) respectively. The blood products support, the antibiotics used, and total environment protection duration decreased. Acute GVHD presented in 7 patients (50.0%). Four patients died in acute GVHD and infection on days of +73, +41 +57 and +49. The disease free survival days after Allo-PBSCT in the 10 patients was +137 (+91–+240) days. It is suggested that Allo-PBSCT probably has some advantage than that of Allo-BMT.